PHASE III NEARS: Cubist Pharmaceuticals has a promising antibiotic--daptomycin--that the company hopes to have in Phase III clinical trials in late 1998 or early 1999. Bacteria are back. Following the discovery and introduction into medicine of penicillin in 1941, intense research in microbiology produced a potent armament of antibiotics that all but eliminated a variety of infectious diseases. With this success, many large pharmaceutical companies scaled back research and development of new
 PHASE III NEARS: Cubist Pharmaceuticals has a promising antibiotic--daptomycin--that the company hopes to have in Phase III clinical trials in late 1998 or early 1999. |
Data collected by the Synercid Microbiology Assessment of Resistance Trends (SMART)--a surveillance project run by the State University of New York (SUNY) at Buffalo and the University of Iowa College of Medicine--show increasing drug resistance in the United States. More than 31 percent of 17,000 bacterial isolates ...
Add The Scientist as a preferred Google source to see more of our trusted coverage.
When Barry Hicks set out to photograph thrombolites, thousands of unexpected visitors photobombed his underwater images.
View this Issue
Explore strategies for improving recombinant adeno-associated virus production in transient HEK293 suspension cultures while maintaining vector quality and supporting scalable viral vector manufacturing.
Discover how tissue-resident memory T cells develop within the respiratory tract and how these findings are advancing respiratory virus immunity, vaccine research, and high-throughput immune profiling.
Bench architecture, primer design, and liquid handling set an assay's limit as throughput climbs.
Explore emerging mechanisms of immune checkpoint inhibitor resistance in hepatocellular carcinoma (HCC) and how combination immunotherapy strategies may improve antitumor immune responses and patient-specific treatment approaches.
European customers can now subscribe to Sino Biological’s newsletter to receive a special gift and unlock access to EliteScience benefits.
Sino Biological’s trial program enables qualified customers to evaluate SuperNuclease Pro in their specific bioprocessing applications, facilitating faster technology assessment and informed decision-making during process development
This release expands on Sino Biological's comprehensive Tau protein product portfolio, designed to accelerate neurodegenerative disease research.
Resipher measures cellular respiration (OCR) continuously in standard 96-well plates inside your incubator, for days to weeks. No media swaps, dyes, or transfers. A live-cell functional readout for drug safety, metabolism, and mitochondrial health.
